Abstract: The present invention is a method of manufacturing an eye lens material having a process in which a phosphorylcholine group-containing chemical compound represented by the following formula (1) is reacted and covalently bonded onto the surface of an eye lens material wherein a chemical compound having an end amino group is introduced to said eye lens material and then the chemical compound represented by the following formula (2) or (3) is introduced through said chemical compound having an end amino group. The object of the present invention is to provide a method of manufacturing a contact lens that prevents protein adsorption.

Abstract: In general, the invention provides a fast-acting, whitening composition containing permanganate. Particular alkali-metal or alkaline-earth metal salts of permanganate; hydrogen peroxide; or an alkali or alkaline-earth metal peroxide; and an acid.

Abstract: New oral rinse solutions and mouthwashes are provided. The oral rinse solutions comprise essential oil and alcohol, supplemented with hydrogen peroxide, and natural extracts. The essential oil and/or alcohol can be provided as part of a base composition. The most preferred base compositions are antiseptic mouthwashes containing the essential oil and/or alcohol. Alternatively, the ingredients can be individually added to the inventive composition. The oral rinse solutions provide antimicrobial activity while soothing oral inflammations and irritations, thus being useful for treating, alleviating, and promoting healing of a wide variety of oral ailments such as periodontal disease (gingivitis and periodontitis), plaque, oral inflammation, toothaches, oral ulcerations, dry socket, dentin hypersensitivity, and halitosis, as well as address aesthetic issues such as bad breath and tooth discoloration.

Abstract: A solid oral sensorial product includes at least one botanical material and at least one phosphate containing stain inhibitor. The botanical material is selected from the group consisting of tobacco, tea, coffee, cocoa, and combinations thereof.

Abstract: The invention is directed to a calcium phosphate complex and the composition containing the same for oral care applications, in which the calcium phosphate complex is formed by chelating the ?-polyglutamic acid (?-PGA) with amorphous calcium phosphate (ACP). This complex can prevent crystallization of ACP and maintain its high solubility. The calcium phosphate complex has superior mucoadhesion properties, allowing it to remain in the mouth longer and offering effective buffering, by which dental caries can be alleviated and prevented.

Abstract: An oral care product comprising a source of calcium ions, a source of phosphate ions, and an insoluble whitening agent for deposition onto the teeth, characterized in that the source of calcium ions and the source of phosphate ions are physically separate prior to the use of the product.

Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.

Abstract: The present invention relates to a novel foam-forming composition suitable for rectal administration of locally-acting pharmaceutically active ingredients, and the product adapted to administer said foam-forming composition. Also, the present invention relates to a method for its preparation. According to the present invention a foam-forming composition is provided which exhibits a high expansion ratio and at the same time conferring optimal appearance of the formed foam to allow sufficient contact time of the active to the target site in the intestine in order to obtain optimal local effect. The composition according to the present inventions provides superior properties for the treatment of rectal diseases.

Abstract: The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial LbL coating containing one or more antimicrobial pepetides. The antimicrobial coating of the invention can impart to the medical an increased surface hydrophilicity and a relatively high antimicrobial activity coupled with low cytotoxicity. The antimicrobial coating of the invention has a minimal adverse effects on the desirable bulk properties of a contact lens, such as oxygen permeability, ion permeability, and optical properties. An antimicrobial coating of the present invention may find particular use in extended-wear contact lenses. In addition, the invention provides a method for making a medical device, preferably a contact lens, having an antimicrobial LbL coating thereon.

Abstract: Provided is a solid composition comprising an iminocarboxylic acid salt, wherein the iminocarboxylic acid salt is 3-hydroxy-2,2?-iminodisuccinic acid and/or a salt thereof. The solid composition comprises 70% by weight or more of the iminocarboxylic acid salt, relative to a solid content except for moisture of the solid composition, and the solid composition comprises 20% by weight or less of moisture, relative to the solid composition. Also a production method of the solid composition, comprising a step of drying an iminocarboxylic acid salt-containing composition is provided.

Abstract: A liquid, substantially anhydrous tooth whitener composition for delivery of a tooth-whitening amount of active whitening ingredient onto teeth, with effective bioadhesion and retention thereof, and, thereupon, sufficient penetration of the ingredient through the tooth enamel, providing efficacious bleaching of stained teeth.

Abstract: Disclosed herein are teeth whitening compositions generally including an oxidizing agent (e.g., a peroxide), and an activating agent that has an emission wavelength between about 400 nm and about 570 nm (e.g., Eosin B). Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.

Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.

Abstract: Soft, flexible highly lubricious coatings for polymeric IOL insertion cartridges that allow IOLs to be easily inserted through small bore cartridges suitable for use with small (less than 3 mm) incisions are provided. These lubricious coatings allow IOLs to be inserted into the eye of a patient without the risk of lens damage or transfer of lubricants to the lens surface during implantation. Specifically, polymeric coatings comprising a matrix polymer having an equivalent weight greater than 5000 g/eq are used to form interpenetrating networks (IPN) on the surface of hydrophobic structural polymers. The IPNs thus formed entrap highly lubricious hydrophilic compounds within the IPN using multi-functional cross linkers.

Abstract: The use of an aromatase inhibitor (AI) in the preparation of a medicament for use in inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female a single dose of the at least one aromatase inhibitor. The use of an aromatase inhibitor (AI) for the preparation of a medicament comprising a single dose of at least one aromatase inhibitor (AI) for administration to an ovulating female suffering from unexplained infertility or other types of ovulatory infertility early in one or more menstrual cycles. Such a medicament may also be administered to an anovulatory female in combination with a plurality of daily doses of follicle stimulating hormone (FSH) whereby the dosage levels of FSH may be reduced. The use of AI in the preparation of a medicament for administration to a female who is a poor responder to FSH, which comprises a combination of a single dose of AI with a plurality of daily doses of FSH is also disclosed.